Neurocrine Biosciences, Inc. (NBIX) Posts Q1 Loss of 17c/Share
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
- Wall St slips as higher Treasury yields weigh on sentiment
- Oil pares losses as market weighs Saudi supply concerns, Middle East tensions
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
Neurocrine Bio. (NBIX) PT Trimmed at Jeffereis, 'Buy' Maintained
May 1, 2014 8:03 AM EDTJefferies analyst Thomas Wei trimmed his price target on Neurocrine Bio. (NASDAQ: NBIX) to $21.00 (from $23.00) but maintained a Buy rating following the company's Q1 update.
Wei comments, "On its 1Q14 call, NBIX focused on its upcoming FDA meeting and subsequent initiation... More
